SQLite Web: event_store.db

Update row 469907 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:7803294cb04a7174","evidence_event_ids":["evt_22bd2c3c35f3"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","company":"TriSalus Life Sciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","article_chars":2334,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_431326476c8197e1","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","content_type":"text/plain","enriched_at":"2026-04-21T07:42:28.645744+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt","source_event_id":"evt_22bd2c3c35f3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"4c2739c6a31a64c6","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-20","2025-07-31","2025-06-23","2027-08-10","2020-09-30"],"entities":[{"asset_class":"equity","name":"TriSalus Life Sciences, Inc.","relevance":"high","symbol":"TLSI","type":"issuer"},{"asset_class":"equity","name":"Frankenius Equity AB","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Series A Convertible Preferred Stock","relevance":"high","symbol":"","type":"security"},{"asset_class":"equity","name":"Common Stock","relevance":"high","symbol":"","type":"security"}],"event_type":"listing","information_gaps":["The cleaned text does not include the full Form 4 tables (e.g., Table I/II/III details beyond the conversion description).","The signal does not provide what changed versus a prior known state (no prior filing/position baseline is included in the provided text).","No explicit statement of whether this was a purchase/sale versus a conversion event in the standard Form 4 transaction fields is shown beyond the narrative conversion description."],"key_facts":["SEC Form 4 filed as of 2026-04-20 for TriSalus Life Sciences, Inc.","Reporting person: Frankenius Equity AB (Frankenius Equity AB).","Conformed period of report: 2025-07-31.","The filing references shares received upon conversion of Series A Preferred Stock reported in Table II.","The conversion was pursuant to an offer commenced on 2025-06-23 under which holders could exchange Preferred Stock for Common Stock equal to (liquidation preference per share price of $10.00 plus accrued and unpaid dividends per share outstanding through August 10, 2027) divided by a $4.00 conversion price per share.","On 2025-07-31, all 230,000 shares of Preferred Stock held by the reporting person were converted into 759,000 shares of Common Stock pursuant to the Offer.","Signature shown: /s/ Ulrika Joreteg dated 2026-04-20."],"numeric_claims":[{"label":"Preferred shares converted (shares)","value":"230,000"},{"label":"Common shares received (shares)","value":"759,000"},{"label":"Offer commencement date","value":"2025-06-23"},{"label":"Conversion date","value":"2025-07-31"},{"label":"Liquidation preference per share price ($)","value":"10.00"},{"label":"Conversion price per share ($)","value":"4.00"},{"label":"Accrued/unpaid dividends through date","value":"2027-08-10"}],"primary_claim":"On 2025-07-31, Frankenius Equity AB converted 230,000 shares of TriSalus Series A Convertible Preferred Stock into 759,000 shares of TriSalus Common Stock pursuant to an offer commenced on 2025-06-23.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"TriSalus Life Sciences, Inc. (TLSI) filed Form 4 on 2026-04-20 reporting Frankenius Equity AB\u2019s conversion of Series A Convertible Preferred Stock into Common Stock. The filing states that 230,000 preferred shares were converted into 759,000 common shares on 2025-07-31 under an offer initiated on 2025-06-23.","topics":["SEC Form 4","insider/reporting owner transaction","conversion of preferred to common","Series A Convertible Preferred Stock","share issuance/conversion ratio"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 TriSalus Life Sciences, Inc. \u00b7 Filed 20260420","ticker":"TLSIW","tickers":["TLSIW"],"title":"TLSIW filed 4","url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-026014.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel